ARCHIVES

Phase III Regorafenib Trial Meets PFS Primary Endpoint

This article is from The Cancer Letter archive.

Vol. 35 No. 6 | June 29, 2012

Download PDF Visit The Full Archive

Related Articles

Women’s Health: Treatment to Move Toward Pre-Cancer, Klausner Says

December 5, 1997

Bypass Budget For FY Seeks $1.189 Billion, Would Fund 1,018 Competing Grants, Restore Cuts

May 20, 1983

Natcher Subcommittee Kills Recision, Save NCI $17 Million

May 2, 1980

RFAs Available: Silicone And Immune Response; Role Of Metallotionein; Dietary Fat Biomarkers

September 11, 1992

ACCR Considers Foriend Membership, Meeting With ASCO

June 14, 1991

Committee Recommends FDA Approval Of Three New Drugs For Cancer Treatment

March 27, 1998